AVADEL PHARMACEUTICALS PLC — Director's Dealing 2026

Feb 18, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AVADEL PHARMACEUTICALS PLC (AVDL)
CIK: 0001012477
Period of Report: 2026-02-13

Reporting Person: Weiss Asset Management LP (Former 10% Owner)
Reporting Person: WEISS ANDREW M (Former 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-02-13	Ordinary Shares	S	11112052	$21	Disposed	0	Indirect

Footnotes

F1: Represents the cash portion of the consideration paid to shareholders upon the closing of the acquisition of the Issuer by Alkermes plc. In connection with such transaction, each outstanding share was automatically converted into the right to receive $21.00 per share in cash, plus a contingent value right to receive a payment of $1.50 in cash if a specified milestone is achieved.

F2: Shares reported herein represent shares beneficially owned by two private investment funds for which Weiss Asset Management LP serves as investment manager. WAM GP LLC is the general partner of Weiss Asset Management LP and Andrew Weiss is the Manager of WAM GP LLC. All of Weiss Asset Management LP, WAM GP LLC, and Andrew Weiss disclaim beneficial ownership of the shares reported herein except to the extent of their pecuniary interest therein.